<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37104882</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1090-2104</ISSN><JournalIssue CitedMedium="Internet"><Volume>662</Volume><PubDate><Year>2023</Year><Month>Jun</Month><Day>25</Day></PubDate></JournalIssue><Title>Biochemical and biophysical research communications</Title><ISOAbbreviation>Biochem Biophys Res Commun</ISOAbbreviation></Journal><ArticleTitle>Suppression of TDP-43 aggregation by artificial peptide binder targeting to its low complexity domain.</ArticleTitle><Pagination><StartPage>119</StartPage><EndPage>125</EndPage><MedlinePgn>119-125</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2023.04.064</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0006-291X(23)00481-3</ELocationID><Abstract><AbstractText>TAR DNA-binding protein 43 (TDP-43), aggregation prone protein, is a potential target of drug discovery for amyotrophic lateral sclerosis. The molecular binders, targeting the disordered low complexity domain (LCD) relevant to the aggregation, may suppress the aggregation. Recently, Kamagata et&#xa0;al. developed a rational design of peptide binders targeting intrinsically disordered proteins based on contact energies between residue pairs. In this study, we designed 18 producible peptide binder candidates to TDP-43 LCD by using this method. Fluorescence anisotropy titration and surface plasmon resonance assays demonstrated that one of the designed peptides bound to TDP-43 LCD at 30&#xa0;&#x3bc;M. Thioflavin-T fluorescence and sedimentation assays showed that the peptide binder suppressed the aggregation of TDP-43. In summary, this study highlights the potential applicability of peptide binder design for aggregation prone proteins.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kamagata</LastName><ForeName>Kiyoto</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Katahira 2-1-1, Aoba-ku, Sendai, 980-8577, Japan. Electronic address: kiyoto.kamagata.e8@tohoku.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanbayashi</LastName><ForeName>Saori</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Katahira 2-1-1, Aoba-ku, Sendai, 980-8577, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koda</LastName><ForeName>Shuichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Daiichi Sankyo Co. Ltd., Tokyo, 140-8710, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kadotani</LastName><ForeName>Akito</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Daiichi Sankyo RD Novare Co. Ltd., Tokyo, 134-0081, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ubukata</LastName><ForeName>Osamu</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Daiichi Sankyo RD Novare Co. Ltd., Tokyo, 134-0081, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tashima</LastName><ForeName>Takumi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Daiichi Sankyo Co. Ltd., Tokyo, 140-8710, Japan. Electronic address: tashima.takumi.r2@daiichisankyo.co.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biochem Biophys Res Commun</MedlineTA><NlmUniqueID>0372516</NlmUniqueID><ISSNLinking>0006-291X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064267">Intrinsically Disordered Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064267" MajorTopicYN="Y">Intrinsically Disordered Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of competing interest Shuichi K and T.T. are employees of Daiichi Sankyo Co., Ltd. O.U. and A.K. are employees of Daiichi Sankyo RD Novare Co., Ltd. K.K is a recipient of the collaborative study grant from Daiichi Sankyo Co., Ltd.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>27</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>27</Day><Hour>18</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37104882</ArticleId><ArticleId IdType="doi">10.1016/j.bbrc.2023.04.064</ArticleId><ArticleId IdType="pii">S0006-291X(23)00481-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>